A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China by Hui Huang et al.
Huang et al. BMC Pulmonary Medicine 2014, 14:8
http://www.biomedcentral.com/1471-2466/14/8RESEARCH ARTICLE Open AccessA retrospective study of microscopic polyangiitis
patients presenting with pulmonary fibrosis in
China
Hui Huang1†, Yan xun Wang1†, Chun guo Jiang1, Jia Liu1, Ji Li2, Kai Xu3 and Zuo jun Xu1*Abstract
Background: Pulmonary involvement is a common feature of MPA. Although alveolar hemorrhage is the most
common pulmonary manifestation of MPA, a few recent studies have described instances of MPA patients with
pulmonary fibrosis. Pulmonary fibrosis was seen to predate, be concomitant with, or occur after the diagnosis of
MPA. The goal of this study was to describe the clinical features and prognosis of microscopic polyangiitis (MPA)
patients whose initial respiratory presentation was pulmonary fibrosis.
Methods: We conducted a retrospective analysis of 19 MPA patients who presented with pulmonary fibrosis at
Peking Union Medical College Hospital between 1990 and 2012.
Results: Of 67 total MPA cases, 19 patients presented with pulmonary fibrosis. There were 8 males and 11 females, with
a median age of 63.6 years. Common clinical manifestations included fever (89.5%), cough (84.2%), dyspnea (78.9%) and
velcro rales (84.2%). Eleven patients experienced weight loss, several had kidney involvement, and most had an increased
erythrocyte sedimentation rate and C-reactive protein. All were positive for myeloperoxidase-anti-neutrophil cytoplasmic
antibody (ANCA), with 6 patients being positive at the time of their initial diagnosis of pulmonary fibrosis. Every patient
had typical features of usual interstitial pneumonia on High-resolution CT. All were treated with corticosteroids and
cyclophosphamide, which lead to an improvement in twelve cases. One of the remaining patients progressed slowly,
whereas six died.
Conclusions: Patients with MPA, who also presented with pulmonary fibrosis in our cohort, were more likely to be older,
female, and have extrapulmonic involvement. Most patients had a delayed positive ANCA. Corticosteroids plus
cyclophosphamide was the remission-induction treatment scheme for all cases. The current prognosis for MPA patients
with pulmonary fibrosis appears to be poor, suggesting that they may be candidates for new therapies.
Keywords: Pulmonary fibrosis, Systemic vasculitis, ANCABackground
Microscopic polyangiitis (MPA) is a common cause of
pulmonary-renal syndrome [1]. Although the kidney is the
most commonly involved organ in MPA, a substantial pro-
portion of patients (25–55%) may also have lung involve-
ment [2]. Although the characteristic clinical manifestation
of MPA in the lung is pulmonary alveolar hemorrhage, a
few recent small studies and case reports have described* Correspondence: xuzj@hotmail.com
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stated.instances of MPA patients with pulmonary fibrosis [3-7]. In
these studies, pulmonary fibrosis was seen to predate, be
concomitant with, or occur after the diagnosis of MPA. In
order to facilitate the recognition, diagnosis, and prognosis
of this uncommon disease, we now describe the clinical,
radiological, and immunological characteristics, as well as
the outcomes of 19 MPA patients whose initial lung mani-
festation was pulmonary fibrosis.Methods
We used a computer-assisted search to identify 67
patients hospitalized with MPA (according to the
2012 revised International Chapel Hill ConsensusLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Union Medical College Hospital between January 1st
1990 and January 1st 2012. A review of the medical re-
cords and radiological images revealed 19 cases whose
initial respiratory manifestation was consistent with a
usual interstitial pneumonia (UIP) pattern or a possible
UIP pattern according to the ATS/ERS/JRS/ALAT
statement [9]. Informed consent was obtained from
every subject and/or their family. This study was ap-
proved by the Peking Union Medical College Hospital
review board.
Patients’ characteristics were recorded from their
medical records, and their high-resolution computed
tomography (CT) images were downloaded from our
hospital’s image bank. Three radiological specialists
conducted a consensus reading of the CT images. Pa-
tients’ age, sex, symptoms at presentation, physical
examination, laboratory and radiological findings,
treatment, and outcomes were analyzed. Data are
expressed as mean ± standard deviation (SD) for con-
tinuous variables and as percentages for categorical







Dyspnea Hemoptysis Renal diseas
1 66/F + 5 + - -
2 71/M + 2 + - Hematuria CR
3 68/M + 0 + - Hematuria,
Proteinuria
4 44/M + 0 + - Ematuria
5 62/M + 12 + - Hematuria
6 64/F + 4 + - -
7 64/F + 0 + + -
8 74/F + 6 - - Hematuria
9 47/F + 0 - - -
10 75/F + 0 - - RPGN
11 51/M + 0 + - ARF
12 72/M + 15 - + ARF
13 50/M - 10 + + -
14 59/F + 0 + - -
15 68/F + 5 + + Proteinuria
16 63/F + 0 + - -
17 70/F - 3 + - Hematuria,
proteinuria C
18 69/F + 3 + - Hematuria
19 72/M + 10 + - Hematuria,
proteinuria
M male, F female, CRF chronic renal failure, RPGN rapidly progressive glomerulonepResults
Demographics and clinical manifestations
The clinical characteristics of the 19 MPA patients in-
cluded in this study cohort are summarized in Table 1.
The study group consisted of 8 male and 11 female pa-
tients with a mean age of 63.6 years (range between 44–
75 years of age). Only 2 patients were younger than 40
years of age, and 3 patients were between 50 and 60
years of age. As HRCT was widely used in our hospital
during the winter of 2003, three cases without HRCT,
which were admitted before 2004 were excluded. All of
the patients in the cohort were admitted between 2004
and 2011.
Constitutional symptoms included fever (89.5%, with 2
patients having high-grade fever), weight loss (57.9%,
mean 6.8 kg, range 2–15 kg), fatigue (47.4%), and loss of
appetite (26.3%). There were 7 cases (36.8%) that had
fever before the diagnosis of pulmonary fibrosis. Among
these 7 cases, one patient’s fever was relieved after anti-
biotics, while the others were relieved after the adminis-
tration of corticosteroids. The other 12 cases (63.2%)






- Myalgia - 1:40/69 Progressed
F + Myalgia - 1:80/131 Improved
- - - 1:80/177 Improved
+ Myalgia - 1:640/322 Improved
- Fatigue - 1:80/98 Improved
+ - - 1:40/66 Improved
- - Eczema- like
rash
1:40/56 Improved




- - - 1:80/116 Improved
- - - 1:320/243 Died
- - - 1:40/80 Died
- - - 1:160/289 Died
- - - 1:80/127 Improved
- Myalgia - 1:80/115 Improved







+ Myalgia - 1:160/356 Improved
- - Purpura- like
rash
1:160/312 Died
hritis, ARF acute renal failure, proteinuria: urine protein > 150 mg/24 h.
Figure 1 Patient with pulmonary fibrosis had positive ANCA at
her initial screening: A 64-year-old woman complained of
cough and exertional dyspnea. She had UIP-pattern on chest CT:
reticular opacities and honeycombing with basal and peripheral
distribution. But her ANCA showed a myeloperoxidase of 196 EU
and she was diagnosed with MPA. She was then treated with
corticosteroids and cyclophosphamide and had a good outcome.
Figure 2 Patient with pulmonary fibrosis had delayed final
diagnosis of MPA: A 71-year-old male diagnosed with
idiopathic pulmonary fibrosis by surgical lung biopsy. A chest
CT showed reticular shadows in the basal aspect of each lung. He was
treated with 1800 mg/d N-Acetylcysteine. Fourteen months later, his
urinalysis revealed hematuria secondary to glomerulonephritis. And
he had an intermittent fever for 2 months with an ANCA of 1:40.
Percutaneous renal biopsy showed focal segmental necrotizing
glomerulonephritis and glomerular crescents. He was diagnosed
with MPA and treated with corticosteroids and cyclophosphamide.
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13 years). Antibiotics were not effective for the fever of
these patients, but corticosteroids were effective.
Respiratory symptoms included cough (84.2%), sputum
(68.4%), hemoptysis (21.1%) and dyspnea (78.9%). Only two
patients had clubbing, whereas Velcro rales could be heard
in the majority of cases (84.2%). At least one extrapulmonic
organ was affected in most cases (Table 1), with nephropa-
thy being the most common. Eye involvement, including
iridocyclitis, scleritis, and keratitis, was reported in 3 cases.
Two cases had central nervous system disease, with demye-
lination seen by magnetic resonance imaging (MRI). One
patient had a peptic ulcer and presented with gastrointes-
tinal bleeding.
Laboratory tests
All patients in the cohort were initially given complete
blood counts (CBC), urinalysis, biochemical tests (including
liver, renal function, and electrolyte levels), erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), anti-
nuclear antibody (ANA), anti-extractable nuclear antigen
(ENA) and anti-neutrophil cytoplasmic antibody (ANCA)
analyses. Peripheral white blood cell counts ranged
from 5.6 × 109/L to 31.2 × 109/L (mean 11.3 × 109/L), with
neutrophils comprising the largest portion (mean, 76.2%,
range, 50.1-95.2%). Eight cases had variable anemia with
hemoglobin ranging from 8.2 to 10.8 g/L. Most patients
had elevated ESR and CRP (94.7% and 78.9%, respectively),
and only 7 cases (36.8%) had normal urinalysis and/or renal
function (Table 1). Furthermore, all 19 patients (100%) were
myeloperoxidase (MPO)-ANCA-positive (range, 43 – > 200
EU; healthy normal control values are < 10 EU as measured
by ELISA), with 6 patients (31.6%) being ANCA-positive at
the time of diagnosis of pulmonary fibrosis. In the other 13
cases, patients became ANCA-positive during the follow-
up period for pulmonary fibrosis and had a mean delay of
9.5 months (range, 4 months to 13 years). Four patients did
not become ANCA-positive until more than 12 months
after the initial diagnosis of pulmonary fibrosis. Anti-
proteinase-3 and anti-glomerular basement membrane
antibodies were negative in all patients.
Bronchoalveolar lavage (BAL) was performed on 5 pa-
tients, and BAL fluid analysis showed neutrophil per-
centages of 4%, 9%, 16%, 32%, and 38% with lymphocyte
percentages of 6%, 10%, 15%, 40%, and 41%, respectively.
None of these patients had an elevated eosinophil level.
CT scan images and pulmonary function tests
Since all 19 patients were diagnosed with MPA after
2004, they all had high-resolution CT images (HRCT;
Figure 1 and 2) (Informed written consent was obtained
for the publication of individual personal information
from these two patients). The most common feature in
each patient was reticular shadows, with approximately
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patients (10/19) had honeycomb lesions (approximately
5-31% of the whole lung), and 2 patients had minimal
ground-glass opacities (both were less than 5%). All of
the shadows were predominant in both lower lobes of
the lungs and had outer zone predominance. Eleven pa-
tients received pulmonary function testing (PFT) upon
the diagnosis of pulmonary fibrosis. Among them, PFT
disclosed a restrictive pattern of ventilation and de-
creased gas diffusion, with a total lung capacity from
48.2% to 72.8% and a carbon monoxide transfer factor
(DLCO) from 30% to 76%.
Echocardiography and electromyography
Echocardiography was carried out in fourteen patients,
revealing pulmonary artery hypertension in 4 (mean,
55 mmHg; range 45-75 mmHg; 1 mmHg = kPa). However,
all 14 patients had a normal ejection fraction. Electromyog-
raphy results were available for 7 patients, which revealed
peripheral neuropathy in 4 patients.
Tissue biopsy and pathological results
Four patients received a transbronchial lung biopsy, with
fibroblast foci found in only one case. Another patient
was diagnosed with usual interstitial pneumonia follow-
ing a surgical lung biopsy. Kidney biopsies were carried
out in 2 cases, and both showed segmental and necrotiz-
ing glomerulonephritis. Finally, 4 patients underwent
muscle biopsies, revealing vasculitis in 1 patient.
Pulmonary fibrosis and MPA
Within 2 to 6 weeks of their initial diagnosis, six of the
patients diagnosed with MPA had pulmonary fibrosis.
Pulmonary fibrosis was seen to predate the diagnosis of
MPA for the other 13 cases, with a mean delay of
9.5 months (range, 4 months to 13 years). Two of the
cases had been misdiagnosed as idiopathic pulmonary fi-
brosis for more than 2 years. They were treated with
BIBF1120 (a new drug made by Boehringer Ingelheim in
clinical trials) for seven months and pirfenidone for 12
months respectively. Antibiotics were prescribed for
fever, but were ineffective. After stopping BIBF1120 and
pirfenidone, both patients still had a fever. Both patients
had microscopic hematuria and kidney biopsies were ar-
ranged for both of them. Both showed segmental and
necrotizing glomerulonephritis. Within one and four
months of the biopsy, they had a positive ANCA re-
spectively. None of the cases had pulmonary fibrosis
after the diagnosis of MPA.
Treatment and outcomes
The median follow-up was 29.9 months (range, 8–
93 months). All patients in the cohort were treated with
corticosteroids and cyclophosphamide in the remissionstage. According to the 2000 guidelines of IPF, all of the
patients who had pulmonary fibrosis before the diagnosis
of MPA were given small dosages of corticosteroids: 0.5-
0.6 mg/kg/d prednisone was prescribed. With the diagnosis
of MPA, the initial doses ranged from 1 mg/kg to 2 mg/kg
per day for 16 of the cases. Three cases with acute
renal failure were given intravenous methylprednisolone
1000 mg for 3 days and tapered to prednisone 1 mg/kg per
day. The initial dose of cyclophosphamide was 2 mg/kg/d
every day for at least 3 months, and then tapered to 1–
1.5 mg/kg per day. Some of the cases that were misdiag-
nosed with IPF were treated with AZA. Additionally, 3
patients were treated with hemofiltration or hemodialysis
due to renal failure. Twelve cases had a lessening of symp-
toms, with another patient progressing slowly, and six pa-
tients dying. Of the six patients that died, two had an
exacerbation of their pulmonary fibrosis; both of them had
diffuse alveolar hemorrhage that was diagnosed by BAL.
One of the two patients also had complicated acute renal
failure. The cause of death in the remaining four cases was
severe pulmonary infection and respiratory failure, which
occurred during the steroid and immunosuppressant treat-
ment period.
Discussion
Nada et al. first reported ANCA-associated pulmonary
fibrosis in 1990 [10]. Since then, several additional
reports have described ANCA-, MPO-ANCA-, and MPA-
associated pulmonary fibrosis [3-7,11,12]. Although pul-
monary fibrosis can be present at the time of MPA
diagnosis, or manifest months to years prior to or after
MPA diagnosis, cases in our cohort all had pulmonary
fibrosis as an initial pulmonary manifestation of MPA.
About two thirds of them had a delayed diagnosis of
MPA of more than 4 months.
MPA has a slight male predominance (male-to-female
ratio: 1.8:1), with an average age of onset between 50–
60 years [2]. Our cohort had an older female predomin-
ance, which differs from the normal distribution of MPA
patients both with and without pulmonary fibrosis; it is also
different from most prior studies of MPA-associated pul-
monary fibrosis. However, Eschun, Mink, and Sharma’s
report describing pulmonary fibrosis as a presenting MPA
manifestation reported a 1:1 male-to-female ratio (3 men, 3
women) [3]. Furthermore, in our study, there were no dra-
matic differences in HRCT manifestations and pulmonary
function characteristics between patients with MPA-
associated pulmonary fibrosis and typical IPF patients. Add-
itionally, according to the 2011 IPF guidelines, a diagnosis
of IPF can be made by HRCT findings suggestive of IPF.
Based on the guidelines and our results, we should include
MPA in the differential diagnosis of a cause of IPF, espe-
cially when the patient is female. This also indicates the
need for a follow-up ANCA test.
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whereas extrapulmonary manifestations were more com-
mon. Most patients had constitutional symptoms, such as
fever and weight loss similar to previous reports [7]. Ele-
vated CRP and ESR and abnormal urinalysis and/or renal
function were also common in our patients. This indicates
that pulmonary fibrosis patients who present without club-
bing but present with extrapulmonary manifestations and/
or renal damage (especially when accompanied by fever),
may indicate the need for an ANCA test for the final diag-
nosis. These patients should not be considered to only have
pulmonary fibrosis as a complication of a lung infection.
Pulmonary involvement occurs in 30-70% of MPA cases
[11], with the classic pulmonary manifestation being diffuse
alveolar hemorrhage caused by pulmonary capillaritis
[2,13]. Some studies have suggested that subclinical intraal-
veolar hemorrhage may play a role in the development of
pulmonary fibrosis in MPA [14-16]. However, in our study
only 21.1% of patients had hemoptysis, and none of the
lung biopsies showed alveolar hemorrhage. This is in agree-
ment with Hervier et al., [5] and indicates that pulmonary
hemorrhage might not be the root cause of MPA-
associated fibrosis.
In accordance with previous reports [3,5,11], all of our
cases were positive for MPO-ANCA. Most cases of other
published studies were also MPO-ANCA positive. Diffuse
alveolar hemorrhage, which has been reported in 12-55% of
MPA patients, has been the classic pulmonary manifest-
ation. Furthermore, 50-75% of cases are ANCA positive [2].
Using an animal model for anti-MPO-associated pulmon-
ary vasculitis, Foucher et al. [17] found that MPO-ANCA
plays a pathogenic role for generalized pulmonary tissue
injury in ANCA-associated vasculitis. However, whether
MPO positivity is a predisposing factor for pulmonary
fibrosis in MPA patients is not yet understood.
Similar to the results in the studies by Eschun et al [3]
and Foulon et al. [4], most of our cohort cases had pulmon-
ary fibrosis before the diagnosis of MPA. About one third
of cases were diagnosed with MPA during the search for
secondary causes of pulmonary fibrosis. That was different
from the Tzelepis’ [7] and Hervier’s [5] study. In their co-
hort, pulmonary fibrosis was present in 36- 67% patients at
the time of diagnosis, and 21-25% patients had pulmonary
fibrosis preceding the other findings of MPA.
An induction of remission treatment followed by main-
tenance therapy is recommended for most MPA patients,
especially if they present with glomerulonephritis. While
90% of MPA patients achieve remission on this regimen,
there is no consensus on a therapy regimen for MPA
patients whose main manifestation is pulmonary fibrosis. In
one study, none of the 12 patients improved while on
immunosuppressive therapy [5]. In another study, corti-
costeroids and/or another immunosuppressive drug
were given for most patients with MPO-ANCA-positivepulmonary fibrosis [11]. However, their prognosis was simi-
lar to IPF patients. Finally, one study showed significantly
greater all-cause mortality among MPA patients with pul-
monary fibrosis, leading the authors to postulate that pa-
tients with MPA-associated pulmonary fibrosis have an
extremely poor prognosis [7]. However, in a study by
Arulkumaran et al. [12], there was no difference in mortal-
ity between patients with MPA vasulitis alone and MPA-
associated interstitial lung disease, leaving the impact of
MPA-associated pulmonary fibrosis on mortality uncertain.
Although all patients in our study were treated with corti-
costeroids and immunosuppressant therapy, one patient
progressed slowly, two patients had an exacerbation of pul-
monary fibrosis, and 6 patients died. Mycophenolate mofe-
til [18] and rituximab [19] have previously been used as
alternatives to cyclophosphamide for MPA patients (most
of them in patients with renal manifestations), and the re-
sults have shown that they are non-inferior alternatives to
cyclophosphamide. These new approaches might be tried
in the future to improve the prognosis of MPA-associated
pulmonary fibrosis.
Our study had limitations because of the retrospective
nature, reliance on clinical notes for data collection, the
small patient numbers, and the severity of some cases. First,
not all patients had undergone extensive pulmonary screen-
ing, including pulmonary function testing (PFT) and bron-
choalveolar lavage. This resulted in an underestimation of
the character and possibly the prognostic value of the PFT
and BAL abnormalities seen in patients with pulmonary fi-
brosis of MPA. In addition, not all of the patients received a
kidney biopsy. Because of this we could not describe the
type of renal involvement for them. Although all cases were
treated with corticosteroids and cyclophosphamide, the
treatment regimes were heterogeneous. Given the rarity of
this condition, multicenter collaboration was required to
pool the numbers and to clarify the epidemiology, clinical
features, optimal treatment strategies, and prognosis for
Chinese MPA patients who had pulmonary fibrosis.
Conclusions
Patients with MPA whose initial respiratory presentation
was pulmonary fibrosis in our cohort, were more likely to
be older, female, and have extrapulmonic involvement.
Most patients had a delayed positive ANCA. The current
prognosis for MPA patients with pulmonary fibrosis ap-
pears to be poor. New drugs may also be tried in order to
improve prognosis of these patients.
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